Neutralizing human anti-IGFR antibody
US7217796B2 · kind B2 · utility
60Cited by
16References
81Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2003 |
| Grant date | May 15, 2007 |
| Priority date | — |
| Expiry date | Dec 22, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.